Summary
Pfizer Inc. (PFE) reported $13.28 billion in total revenues for the second quarter of 2024, a slight increase of 2% year-over-year, driven by operational growth from legacy Seagen products and continued demand for its Vyndaqel family and Eliquis, partially offset by declines in Comirnaty and Xeljanz. For the first six months of 2024, total revenues were $28.16 billion, down 11% year-over-year, primarily due to significant declines in Comirnaty and Paxlovid sales. The company experienced a net loss attributable to Pfizer Inc. common shareholders of $41 million for the quarter, a stark contrast to the $2.33 billion net income reported in the same period last year. This shift is largely attributable to increased restructuring charges and acquisition-related costs, unfavorable movements in equity securities, and higher net interest expenses. Despite these challenges, Pfizer is actively pursuing cost realignment and manufacturing optimization programs, signaling a focus on improving future profitability and aligning costs with evolving revenue expectations.
Financial Highlights
54 data points| Revenue | $13.28B |
| Cost of Revenue | $3.30B |
| Gross Profit | $9.98B |
| SG&A Expenses | $3.72B |
| Interest Expense | $778.00M |
| Net Income | $41.00M |
| EPS (Basic) | $0.01 |
| EPS (Diluted) | $0.01 |
| Shares Outstanding (Basic) | 5.67B |
| Shares Outstanding (Diluted) | 5.70B |
Key Highlights
- 1Total revenues for Q2 2024 were $13.28 billion, a 2% increase year-over-year, driven by operational growth from new acquisitions and key product lines, partially offset by declines in COVID-19 products.
- 2Net income attributable to Pfizer Inc. common shareholders for Q2 2024 was a loss of $41 million, a significant decrease from a profit of $2.33 billion in Q2 2023, largely due to increased restructuring charges and acquisition-related costs.
- 3The company incurred substantial restructuring charges and acquisition-related costs of $1.25 billion in Q2 2024, a significant increase from $214 million in the prior year, reflecting ongoing cost realignment and manufacturing optimization programs.
- 4Revenues from the Vyndaqel family increased by 71% operationally year-over-year in Q2 2024, highlighting strong demand for these products.
- 5Comirnaty sales saw a significant year-over-year decline of 87% operationally in Q2 2024, reflecting the transition to commercial markets and seasonal demand patterns.
- 6Pfizer reported $6.05 billion in cash and cash equivalents and short-term investments as of June 30, 2024, indicating a decrease from $12.69 billion at the end of 2023, impacted by acquisition spending and cash deployment.
- 7The company sold approximately 30% of its investment in Haleon in March 2024 for $3.5 billion, recognizing a gain of $150 million.